Corium
Kevin Ostrander has extensive experience in business development and leadership roles in the pharmaceutical industry. Kevin is currently serving as the Chief Business Officer at Corium, Inc. Prior to this, they held the position of Vice President of Business Development at ApiJect, and SVP of Business Development at BioDelivery Sciences International. Kevin also served as the Head of North America Business Development at Glenmark Pharmaceuticals, and Executive Director of Business Development and Licensing at Sandoz. Kevin has held various other leadership roles in companies such as Mylan Specialty, Eurand, Watson Pharmaceuticals, NexMed Pharmaceuticals, and Cardinal Health.
Kevin Ostrander has a diverse educational background. Kevin holds an M.B.A. in International Business from the Saint Joseph's University - Erivan K. Haub School of Business. Additionally, they earned a B.S. in Biology/Chemistry from the University at Albany, SUNY. Kevin furthered their education by obtaining an M.S. in Regulatory Affairs/Quality Assurance from the Temple University School of Pharmacy.
This person is not in any offices
Corium
Corium is a commercial-stage biopharmaceutical company that is leading the development and commercialization of central nervous system (CNS) healthcare therapies that provide clinicians with important treatment options for patients, their families, and their caregivers. Collaborating with some of the world's largest pharmaceutical and consumer product companies, we have a track record and depth of experience in taking products from concept, through development, to manufacturing and final commercialization.